Cancer molecular Dx firm seeks to obtain $6.6 million

12/24/2012 | GenomeWeb Daily News (free registration)

Epigenomics hopes to obtain $6.6 million in a funding round it plans to launch next month. The company is the maker of the Epi proColon test, a blood-based assay for screening colorectal cancer. Proceeds from the planned fundraising will be used to finance the company's operations as well as expand its capabilities for product distribution.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
PacificSource
Boise, ID